Experienced in Hemolytic Anemia

Dr. Joseph W. Rosenthal

Pediatric Hematology Oncology
1500 E Duarte Rd, 
Duarte, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Hemolytic Anemia
1500 E Duarte Rd, 
Duarte, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Rosenthal is a Pediatric Hematologist Oncology provider in Duarte, California. Dr. Rosenthal is rated as an Experienced provider by MediFind in the treatment of Hemolytic Anemia. His top areas of expertise are Sickle Cell Disease, Leukemia, Hemoglobinopathy, Graft Versus Host Disease (GvHD), and Bone Marrow Transplant.

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles and participated in 4 clinical trials in the study of Hemolytic Anemia.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

1500 E Duarte Rd, Duarte, CA 91010

Additional Areas of Focus

Dr. Rosenthal has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Pilot Study of Nonmyeloablative Regimen Using Total Marrow and Lymphoid Irradiation for Irradiation Sparing of Bystander Organs in Hematopoietic Cell Transplantation From Matched Related or Unrelated Donor in Patients With Sickle Cell Disease
A Pilot Study of Nonmyeloablative Regimen Using Total Marrow and Lymphoid Irradiation for Irradiation Sparing of Bystander Organs in Hematopoietic Cell Transplantation From Matched Related or Unrelated Donor in Patients With Sickle Cell Disease
Enrollment Status: Recruiting
Publish Date: December 31, 2024
Intervention Type: Radiation, Procedure, Drug
Study Phase: Phase 1
A Pilot Study To Evaluate The Safety And Feasibility of Hematopoietic Progenitor Cell Mobilization With Plerixafor as Part of a Gene Therapy Strategy in Sickle Cell Disease
A Pilot Study To Evaluate The Safety And Feasibility of Hematopoietic Progenitor Cell Mobilization With Plerixafor as Part of a Gene Therapy Strategy in Sickle Cell Disease
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Drug
Study Drug: Plerixafor
Study Phase: Phase 1
Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) During Conditioning for HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Myelodysplasia or Acute Leukemia
Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) During Conditioning for HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Myelodysplasia or Acute Leukemia
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Cyclophosphamide, Fludarabine Phosphate, Mycophenolate Mofetil, Tacrolimus
Study Phase: Phase 1
Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients With COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients With COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2025
Intervention Type: Biological, Drug
Study Drugs: Cyclophosphamide, Pentostatin, Rabbit anti-thymocyte globulin, Tacrolimus, Mycophenolate mofetil, CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
Study Phase: Phase 1
Allogeneic Stem Cell Transplantation for Patients With Hematological Malignancies Using Multiple Unrelated Cord Blood Units
Allogeneic Stem Cell Transplantation for Patients With Hematological Malignancies Using Multiple Unrelated Cord Blood Units
Enrollment Status: Completed
Publish Date: June 14, 2024
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Filgrastim, Busulfan, Cyclophosphamide, Cyclosporine, Fludarabine, Melphalan, Mycophenolate Mofetil
Study Phase: Not Applicable
A Phase 1 Pilot Study to Evaluate the Safety and Feasibility of Gene Therapy With CSL200 (Autologous Enriched CD34+ Cell Fraction That Contains CD34+ Cells Transduced With Lentiviral Vector Encoding Human γ-GlobinG16D and Short-Hairpin RNA734) in Adult Subjects With Severe Sickle Cell Disease
A Phase 1 Pilot Study to Evaluate the Safety and Feasibility of Gene Therapy With CSL200 (Autologous Enriched CD34+ Cell Fraction That Contains CD34+ Cells Transduced With Lentiviral Vector Encoding Human γ-GlobinG16D and Short-Hairpin RNA734) in Adult Subjects With Severe Sickle Cell Disease
Enrollment Status: Terminated
Publish Date: June 18, 2021
Intervention Type: Biological
Study Phase: Phase 1
View 5 Less Clinical Trials

46 Total Publications

Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.
Journal: Cancer medicine
Published: February 29, 2024
Similar Doctors
Elite in Hemolytic Anemia
Dr. Thomas D. Coates
Pediatric Hematology Oncology
Elite in Hemolytic Anemia
Dr. Thomas D. Coates
Pediatric Hematology Oncology

Childrens Hospital Los Angeles Medical Group Inc

4650 W Sunset Blvd, 
Los Angeles, CA 
 (18.2 miles away)
323-361-8408
Languages Spoken:
English
See accepted insurances

Thomas Coates is a Pediatric Hematologist Oncology provider in Los Angeles, California. Dr. Coates is rated as an Elite provider by MediFind in the treatment of Hemolytic Anemia. His top areas of expertise are Hemoglobinopathy, Anemia, Congenital Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Distinguished in Hemolytic Anemia
Dr. Donald B. Kohn
Pediatric Hematology Oncology
Distinguished in Hemolytic Anemia
Dr. Donald B. Kohn
Pediatric Hematology Oncology
4650 W Sunset Blvd, Ms# 62, 
Los Angeles, CA 
 (18.2 miles away)
323-669-4559
Languages Spoken:
English
See accepted insurances

Donald Kohn is a Pediatric Hematologist Oncology provider in Los Angeles, California. Dr. Kohn is rated as an Elite provider by MediFind in the treatment of Hemolytic Anemia. His top areas of expertise are Severe Combined Immunodeficiency (SCID), Adenosine Deaminase Deficiency, X-Linked Severe Combined Immunodeficiency, Hemoglobinopathy, and Bone Marrow Transplant.

Distinguished in Hemolytic Anemia
Dr. Thomas C. Hofstra
Pediatric Hematology Oncology
Distinguished in Hemolytic Anemia
Dr. Thomas C. Hofstra
Pediatric Hematology Oncology

Childrens Hospital Los Angeles Medical Group Inc

4650 W Sunset Blvd, 
Los Angeles, CA 
 (18.2 miles away)
323-361-8408
Languages Spoken:
English
See accepted insurances

Thomas Hofstra is a Pediatric Hematologist Oncology provider in Los Angeles, California. Dr. Hofstra is rated as a Distinguished provider by MediFind in the treatment of Hemolytic Anemia. His top areas of expertise are Thalassemia, Congenital Hemolytic Anemia, Hemolytic Anemia, and Beta Thalassemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rosenthal's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile